Skip to main content
NIH funding notice PAR-19-252

Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Optional)

Closed on November 8, 2021.

Posted
April 11, 2019
Close date
November 8, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $393,577 in first-year total cost, median $196,789.

Most frequent study sections

  1. Cancer Etiology Study Section[CE]1
  2. Cancer Prevention Study Section[CPSS]1

Most frequent institutions

  1. JOHNS HOPKINS UNIVERSITY1
  2. WASHINGTON STATE UNIVERSITY1
Competing awards under PAR-19-252 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2022Characterizing the contribution of transcription-associated DNA-topoisomerase adducts to mutagenesis in cancer1R21CA264086-01A1ROBERTS, STEVEN AWASHINGTON STATE UNIVERSITY, WA$202,194CE
2020Tracking 30 years of air pollution: Targeted adductomics for cancer prevention1R21CA239154-01A1COLE, ROBERT NGROOPMAN, JOHN DJOHNS HOPKINS UNIVERSITY, MD$191,383CPSS

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.